scholarly journals COVID-19 in Renal Transplant Patient Presenting With Active Typical Symptoms and Resolved Atypical Symptoms

2020 ◽  
Vol 8 ◽  
pp. 232470962094930 ◽  
Author(s):  
Sreedhar Adapa ◽  
Venu Madhav Konala ◽  
Srikanth Naramala ◽  
Subba Rao Daggubati ◽  
Narayana Murty Koduri ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Gastrointestinal Symptoms ◽  
Published Data ◽  
The Novel ◽  
Transplant Recipients ◽  
Atypical Symptoms ◽  
Rapid Transmission ◽  
Novel Coronavirus

The novel coronavirus disease has brought the world to standstill with high infectivity and rapid transmission. The disease caused by novel coronavirus is termed as coronavirus disease 2019 (COVID-19). We present the case of a renal transplant patient who was infected with COVID-19 through community spread and presented with fever and gastrointestinal symptoms. Transplant recipients are particularly vulnerable because of the immunosuppressed state. These patients can shed a virus for a prolonged period and can have a higher load of the virus. There have been no COVID-19 cases transmitted through organ donation. Preinfection immunological impairment can aggravate the severity of the infection. The transplant team plays a crucial role in donor and recipient evaluation and guiding the timing of the transplant. Although specific published data are lacking with regard to transplant recipients, they should follow the same precautions as the general population, like avoiding nonessential travel and practice social distancing.

scholarly journals Fecal microbiota transplantation as an effective treatment for carbapenem-resistant Klebsiella pneumoniae infection in a renal transplant patient

2020 ◽  
Author(s):  
Junpeng Wang ◽  
Xin Li ◽  
Xiaoqiang Wu ◽  
Zhiwei Wang ◽  
Xuan Wu ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Renal Transplant ◽  
Klebsiella Pneumoniae ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Carbapenem Resistant

Abstract Background: In renal transplant recipients, carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is common, and usually associated with severe clinical outcomes due to a lack of effective therapeutics.Case presentation: A 37-year-old female had a CRKP infection one month after the kidney transplantation. Since the effect of the antibiotic therapy was limited, fecal microbiota transplantation (FMT) was performed. FMT resulted in increased richness and diversity of gut microbiota and reduced relative abundance of Klebsiella. After FMT, the infection of the patient caused by CRKP was well controlled without inducing adverse effects.Conclusion: This study demonstrated the therapeutic effect of FMT on CRKP infection, and may shine some light on the treatment of the infections caused by CRKP for the patients after transplantation.

Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient

2002 ◽  
Vol 13 (7) ◽  
pp. 501-503 ◽  
Author(s):  
S L Gayed
Keyword(s):  
Renal Transplant ◽  
Effective Treatment ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Genital Warts ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Imiquimod Cream ◽  
Patient Subgroup ◽  
Genitourinary Medicine

Renal transplant recipients represent a patient subgroup for whom the effective treatment of genital warts poses a significant problem in genitourinary medicine. This case demonstrates the safe and effective treatment of resistant perianal warts in a male renal transplant recipient using imiquimod.

Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient

2002 ◽  
Vol 13 (5) ◽  
pp. 349-351 ◽  
Author(s):  
S L Gayed
Keyword(s):  
Renal Transplant ◽  
Effective Treatment ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Genital Warts ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Imiquimod Cream ◽  
Patient Subgroup ◽  
Genitourinary Medicine

Renal transplant recipients represent a patient subgroup for whom the effective treatment of genital warts poses a significant problem in genitourinary medicine. This case demonstrates the safe and effective treatment of resistant perianal warts in a male renal transplant recipient using imiquimod.

scholarly journals Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients

1998 ◽  
Vol 44 (9) ◽  
pp. 1942-1946 ◽  
Author(s):  
Jan L Cogill ◽  
Paul J Taylor ◽  
Ian S Westley ◽  
Raymond G Morris ◽  
Stephen V Lynch ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Therapeutic Drug ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Significant Difference ◽  
Microparticle Enzyme Immunoassay ◽  
Clinically Significant ◽  
Comparison Data

Abstract We evaluated the MEIA II with blood samples with added tacrolimus (3.0, 5.0, 11.0, and 22.0 μg/L). The assay had acceptable recoveries (99–103%) and intraday imprecision (<16.0%) across the range of concentrations studied, except for the recoveries at 3.0 μg/L (86.3%) and 5.0 μg/L (80.7%). Comparison of liver (n = 116) and renal (n = 113) patient samples measured by MEIA II against HPLC-tandem mass spectrometry (HPLC-MS/MS) found a mean overestimation of 15.6%. From these comparison data it can be calculated that at values of 5 and 20 μg/L in liver or renal transplant patient samples, measured by HPLC-MS/MS, MEIA II will have the corresponding range estimates of 3.6–7.9 μg/L and 20.9–25.4 μg/L, respectively. No clinically significant difference in results, in terms of overestimation or correlation, was observed between the two transplant groups studied. The MEIA II is an improvement on the previous MEIA I and is suitable for the therapeutic drug monitoring of tacrolimus where HPLC-MS/MS is unavailable.

scholarly journals Mucormycosis in a Renal Transplant Recipient: Case Report and Comprehensive Review of Literature

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Tamim Hamdi ◽  
Vanji Karthikeyan ◽  
George J. Alangaden
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Uncontrolled Diabetes ◽  
Solid Organ Transplant Recipients ◽  
Disseminated Mucormycosis ◽  
Prompt Diagnosis

Mucormycosis is a rare but devastating infection. We present a case of fatal disseminated mucormycosis infection in a renal transplant patient. Uncontrolled diabetes mellitus and immunosuppression are the major predisposing factors to infection with Mucorales. Mucorales are angioinvasive and can infect any organ system. Lungs are the predominant site of infection in solid organ transplant recipients. Prompt diagnosis is challenging and influences outcome. Treatment involves a combination of surgical and medical therapies. Amphotericin B remains the cornerstone in the medical management of mucormycosis, although other agents have been used. Newer agents are promising.

scholarly journals IVIG Associated Aseptic Meningitis in a Renal Transplant Patient

2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Tamara Wanigasekera ◽  
Rachel J. Grainger ◽  
Donal J. Sexton ◽  
Colm Magee
Keyword(s):  
Adverse Effect ◽  
Renal Transplant ◽  
Aseptic Meningitis ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Ivig Therapy ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Antibody Mediated Rejection

The management of antibody-mediated rejection in renal transplant recipients involves plasmapheresis with IVIG. Aseptic meningitis is a rare adverse effect of IVIG therapy and is a diagnosis of exclusion. We report a case of a renal transplant patient who developed IVIG associated aseptic meningitis in the context of management of antibody-mediated rejection, four years after transplantation.

scholarly journals An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system

2021 ◽  
Vol 45 (1) ◽  
Author(s):  
Padmalochan Hembram
Keyword(s):  
Immune System ◽  
Dark Side ◽  
Main Body ◽  
The Novel ◽  
Transmission Chain ◽  
The World ◽  
Therapeutic Molecules ◽  
Rapid Transmission ◽  
Novel Coronavirus ◽  
Near Future

Abstract Background Coronavirus disease 19 is a viral infection caused by a novel coronavirus, SARS-CoV-2. It was first notified in Wuhan, China, is now spread into numerous part of the world. Thus, the world needs urgent support and encouragement to develop a vaccine or antiviral treatments to combat the atrocious outbreak. Main body of the abstract The origin of this virus is yet unknown; however, rapid transmission from human-to-human “Anthroponosis” has widely confirmed. The world is witnessing a continuous hike in SARS-CoV-2 infection. In light of the outbreak of coronavirus disease 19, we have aimed to highlight the basic and vital information about the novel coronavirus. We provide an overview of SARS-CoV-2 transmission, timeline and its pathophysiological properties which would be an aid for the development of therapeutic molecules and antiviral drugs. Immune system plays a crucial role in virus infection in order to control but may have dark side when becomes uncontrollable. The host and SARS-CoV-2 interaction describe how the virus exploits host machinery and how overactive host immune response can cause disease severity also addressed in this review. Short conclusion Safe and effective vaccines may be the game-changing tools, but in the near future wearing mask, washing hands at regular intervals, avoiding crowed, maintaining physical distancing and hygienic surrounding, must be good practices to reduce and break the transmission chain. Still, research is ongoing not only on how vaccines protect against disease, but also against infection and transmission.

Sign in / Sign up

Export Citation Format

Share Document